Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.